Korsana Biosciences vs Ovid Therapeutics
Ovid Therapeutics is the larger business, with $7.3m of revenue in fiscal 2025 against $2.1m for Korsana Biosciences (3.5 times as much). Ovid Therapeutics grew faster (1181.3% against 3.7%). Korsana Biosciences kept more of each dollar of sales as profit: a net margin of -170.1% against -240.1%. Korsana Biosciences carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Korsana BiosciencesKRSA, 2025 | Ovid TherapeuticsOVID, 2025 |
|---|---|---|
| Revenue | $2.1m | $7.3m |
| Revenue growth | 3.7% | 1181.3% |
| Net income | −$3.5m | −$17.4m |
| Operating margin | -239.8% | -585.2% |
| Net margin | -170.1% | -240.1% |
| Return on equity | -39.3% | -17.5% |
| Free cash flow | −$3.3m | −$38.3m |
| Cash | $3.2m | $13.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 23 |
| Market value | $138m | $446m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 2 sales |